Juvenile xanthogranuloma

juvenile xanthogranuloma large 1

Juvenile xanthogranuloma is observed in young children, mainly under 24 months of age. In nearly 75% of cases, eruptions occur within the first year of life, and in 15% of cases, they are present at birth.

Cases of xanthogranuloma appearing in adults have been described, typically around the age of 20-30, but they can also occur in the elderly.

With solitary eruptions, the condition is slightly more common in boys than girls, with a ratio of 1.5:1. However, in cases of multiple lesions, the predominance of males over females rises sharply to 12:1. The disease is 10 times more common in children of European descent than in other populations.

Pathogenesis of the disease is unknown. It is a benign tumor composed of differentiated histiocytes non-Langerhans type. Blood lipids are normal. The reason for progressive lipidization (accumulation of lipids) of histiocytes in the absence of hyperlipidemia is not clear. However, it has been shown that adults with xanthogranuloma have increased uptake of low-density lipoproteins and cholesterol synthesis in macrophages. Some suggest that histiocytes may respond in this way to traumatic or infectious factors.

The disease begins with the appearance of pink, reddish-gray macules that rapidly progress to papules, plaques, and nodules. These lesions are moderately firm and elastic to palpation, have well-defined borders, and are often surrounded by a peripheral pink halo. At the onset of the disease, the color of the eruptions ranges from pink to reddish-brown, later becoming pale yellow, orange, and brown with varying shades.

The surface of the lesions is usually smooth, sometimes with prominent skin patterns. Telangiectasias may be observed on the larger formations, and in some cases erosion and ulceration may occur. The most common sites of eruption are scalp, face, neck, upper chest, and less commonly upper and lower extremities and genitalia. Unusual manifestations include eruptions with hyperkeratosis, subcutaneous nodules, and clustered plaques.

In some patients, "Café au lait" patches may be observed, which may indicate an association with neurofibromatosis.

The disease follows a chronic course, with spontaneous involution of the lesions usually occurring within 1-6 years (average 2-3 years). The involution of the lesions begins with central depression and slight softening, eventually leading to shrinkage and disappearance. Hypo- and/or hyperpigmented patches, mild atrophy, or anetoderma may remain.

Small nodular form


juvenile xanthogranuloma small
Characterized by the emergence of small dome-shaped papules measuring 2-5 mm in diameter, scattered throughout the body. In most cases, multiple eruptions are observed, sometimes reaching hundreds. It is more commonly found in children. Disseminated forms have also been described.

Large nodular form


juvenile xanthogranuloma large 2
This is the most common variant of juvenile xanthogranuloma, appearing at any age. It presents as the eruption of one or several nodules measuring 1-2 cm in diameter. Among adults, a single nodule is more frequently observed.

Plaque form


juvenile xanthogranuloma plaque
Characterized by the appearance of single or multiple flat plaques of yellow or orange color, often with irregular borders, sometimes reaching large sizes. Symmetrical localization has been reported in some cases.

Giant form


juvenile xanthogranuloma giant
This rare form of the disease is typically seen in girls under 14 months old. It presents as a nodule larger than 2 cm, often situated in the upper back region. This can be misdiagnosed as a juvenile hemangioma.

Ulcerative form


	juvenile xanthogranuloma ulc
This form involves central ulceration of the xanthogranuloma's surface, causing central depression and a crater-like appearance. It is a rare variant of the large nodular or giant forms.

Oral form


	juvenile xanthogranuloma oral
Characterized by the presence of a single nodule with a red-yellow color, often found on the lateral surface of the tongue or the midline of the hard palate.

Ocular form


juvenile xanthogranuloma ocular
More common in children under 2 years of age, accounting for 10% of cases. It is often unilateral and affects the conjunctiva of the eye, with or without limbal involvement. The combination of ocular and cutaneous forms has been reported in 0.5-1% of cases with single eruptions and up to 40% with multiple eruptions. Common symptoms include conjunctival erythema, photophobia, iris discoloration, and globe enlargement. Serious complications include hyphema (bleeding into the anterior chamber) and glaucoma, which can lead to blindness.

Systemic form


This form occurs in approximately 4% of cases and is associated with cutaneous manifestations in 50% of patients. It is characterized by the formation of granulomas in the muscles, liver, spleen, and lungs. Less commonly, the process may involve bones, testicles and central nervous system, resulting in ataxia, increased intracranial pressure, subdural hemorrhage, developmental delay, non-diabetic diabetes, and other neurologic disorders. Fatal outcomes have been reported in cases of progressive juvenile xanthogranuloma involving the liver in newborns.

The diagnosis is established based on the clinical picture, medical history, and histological examination.

In contrast to X histiocytosis, histiocytes do not tend to penetrate the epidermis, and Langerhans cell granules are not detected by electron microscopy.

Children under 2 years old with multiple eruptions should be under the observation of an ophthalmologist, and those with neurofibromatosis should be under the care of a hematologist.

  • Mastocytoma
  • Spitz Nevus
  • Xanthomas
  • Langerhans cell histiocytosis.
  • Congenital self-healing reticulohistiocytosis
  • Melanocytic Nevus
  • Dermatofibroma
  • Cutaneous reticulohistiocytoma.
  • Pyogenic Granuloma.
juvenile xanthogranuloma dd tab 1
juvenile xanthogranuloma dd tab 2

Patients with cutaneous forms of the disease do not require treatment due to its spontaneous resolution. Surgical excision of lesions may be performed for cosmetic reasons.

In cases of ocular involvement, corticosteroids in the form of eye drops, subconjunctival injections, or oral administration are recommended. Surgery, chemotherapy, or low-dose radiation (300-400 cGy) are used to treat hyphema or glaucoma.

For systemic form, chemotherapy (cytarabine, vincristine), methotrexate, cyclosporine, and high-dose prednisolone are used. Successful use of cladribine has been reported for CNS involvement.